Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.275p -8.66% 2.90p 2,983,010 11:30:22
Bid Price Offer Price High Price Low Price Open Price
2.85p 2.98p 3.20p 2.90p 3.20p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -10.96 -3.92 9.9

Motif Bio (MTFB) Latest News

More Motif Bio News
Motif Bio Takeover Rumours

Motif Bio (MTFB) Share Charts

1 Year Motif Bio Chart

1 Year Motif Bio Chart

1 Month Motif Bio Chart

1 Month Motif Bio Chart

Intraday Motif Bio Chart

Intraday Motif Bio Chart

Motif Bio (MTFB) Discussions and Chat

Motif Bio (MTFB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
10:41:262.871,91454.85O
10:40:552.871,20234.45O
10:40:082.871,82852.39O
10:36:572.9789,3522,658.04O
10:29:522.9830,000895.32O
View all Motif Bio trades in real-time

Motif Bio (MTFB) Top Chat Posts

DateSubject
17/6/2019
09:20
Motif Bio Daily Update: Motif Bio Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTFB. The last closing price for Motif Bio was 3.18p.
Motif Bio Plc has a 4 week average price of 2.90p and a 12 week average price of 2.90p.
The 1 year high share price is 44.90p while the 1 year low share price is currently 2.90p.
There are currently 342,491,023 shares in issue and the average daily traded volume is 5,224,893 shares. The market capitalisation of Motif Bio Plc is £9,932,239.67.
15/5/2019
20:16
gersemi: Four announcements to watch out for in May and June By Andrew Hore - 13/05/2019 Here are four events to look out for in May and June. Motif Bio, Pressure Technologies, TechFinancials and Mereo Biopharma are all set to make announcements that could have a significant effect on each individual share price. - Motif Bio (LON: MTFB) Motif Bio had high hopes for its Iclaprim treatment for acute bacterial skin and skin structure infections. However, these hopes were severely dented. The result of a meeting with the FDA will be significant to getting back on track and a recovery in the share price. The complete response letter from the US FDA was received in February. Motif had hoped that this would enable approval of Iclaprim, but the regulator said it could not approve the new drug application (NDA) in its current form. Concerns about liver toxicity were highlighted. Motif has met with the FDA in order to discuss the points raised by the regulator. By the end of this month or early June, Motif should receive the minutes of the meeting. This will be key to any decision on how Motif can progress with Iclaprim, if at all. Ideally, the meeting will provide a path to marketing approval for Iclaprim. Ten years of exclusivity in the US is available if approval is gained. In March, Motif raised £2.7m at 6p a share and this cash funds the company into June. Further cash will be required, and the amount needed, and whether it can be raised, will depend on the minutes. Positive news from the FDA could make the share price bounce back and make it easier to raise cash. - HTTP://ukinvestormagazine.co.uk/four-announcements-to-watch-out-for-in-may-and-june/
09/4/2019
20:55
bocase: dlm: I think we are talking at cross purposes. I do not dispute what you say but in my previous post I was referring to Northland securities PRICE TARGET of $5 per share. That is what I am saying converts to 19p. ie the price target and not the share price now. As you say $5 divided by 20 and divided by the exchange rate of 1.32 =19p Some on this board were thinking that the $5 price target implied a UK price target of £3.78 without realising the 20:1 ratio So we are in agreement but talking at cross purposes.
04/4/2019
20:47
newtothisgame3: #MTFB average analyst price target is $3.5 per share. This means the stock has a potential increase of 83.25% from where the MTFB share price has been trading recently which is between $1.82 and $1.8999 with one of them, even setting their price target at $5. By Peggy Goldman - April 4, 2019 https://twitter.com/smallcappick/status/1113890691476803584
21/3/2019
17:45
bocase: The meeting on 3rd May will obviously be pivotal. If it is just a labelling issue then that can be resolved. It the new data can be made available without new trials then we could easily see the share price back to 20p or more before approval. If new trials are required then we will see a dilution due to more funding. We can only wait and hope but there is considerable upside from here for the brave and any buying will see the share price rise because most of a mind to sell have already done so To my mind there can only be one sensible decision and that is to hold on
02/3/2019
12:35
pwhite73: Because institutions can settle for a 10% gain on a large number of shares which can be equivalent to a 100% re-valuation of the market cap. For example Motif announces they have a meeting with the FDA on 01/04/2019. The announcement of the meeting can double Motif's valuation from today's £20m to £40m. This would normally lead to a doubling of the share price from 7p to 14p. However under a capital raise program an institution can make available £20m to Motif in cash for shares valued at 7p. When the announcement of the meeting is made investors rush into Motif however instead of the share price doubling the institution sells the stock to investors at 8p. The gain for them is 15% which is equivalent to £3m not bad for two weeks work. The gain for mug PIs who bought at 8p is zero. Most mug PIs are in well over 8p. This is how placings normally work. They make available new shares to new buyers at a price existing buyers can't sell at without incurring a loss. If you're thinking of buying at 7p you should be OK assuming the capital raise is not at 5p!!!.
01/3/2019
08:26
pwhite73: Your $1bn valuation before commercial sales is wildly optimistic. What you also have to bear in mind is a change of ownership from institutions to fickle PIs. Furthermore Motif does not currently have anything like the cash to take the company to commercialisation therefore further capital will be required or a partnership. If Motif wants to keep 100% of its product it will need to raise further case and much more. I do believe there will be a share price rise once the meeting with the FDA is completed but this has to be sensibly tempered against how they intend to raise capital. The share price is not stuck at 7p for nothing.
01/3/2019
08:12
pwhite73: andrewsr - Let me explain. MTFB is currently valued at £20m. If FDA approval values MTFB at £100m that is an £80 million increase. However if the company issues 1.14 billion shares in stages at 7p that is equivalent £80 million. They could issue shares higher than 7p say at 14p and that would be about 600 million shares. So effectively the increased valuation is not reflected in the share price. If you bought your shares when they dropped to 5p you'll be doing fine but if you bought at 7p you'd break even, but many shareholders are in MTFB at far higher prices. In short any approval is already priced into the capital raise. Now a 500% increase to £100m is optimistic on just FDA approval as all mug PIs will race for the door on any rise above their buy price.
24/2/2019
11:56
pwhite73: badger60 and Nobbygnome As I explained you are spread betting. Which means betting on the direction of a share price per point. A share price is 100p if you think its going to drop to 50p you can bet £1000 at £1.00 per penny point. If the share price drops to 50p you have made £500. You can also set stop losses to protect against a swing in the opposite direction. That's how spread betting works. This has nothing whatsoever to do with shorting. You are not borrowing any stock. Your broker may also not be borrowing any stock for they may already be a big holder in IMM (for example). When your broker is having to borrow stock to accommodate your spread bet that is when you may find they are not prepared to take the risk and refuse your bet. Shorting is when you personally request to borrow stock. In my first post on the subject I ended by stating "Only institutions approved by the FCA can short AIM shares." Spreadex would be one of them.
19/2/2019
14:27
sharedgain: Not much came out of the conf call, the best info came from answers to the questions that were raised. For me, the key points were: - No comment on cash runway to the other side of FDA meeting - but cash is being managed very carefully; - A number of parties have expressed an interest in partnering MTFB, but no further comment would be made at this stage; - FDA question relates to elevated liver enzymes; - FDA have agreed to the meeting but MTFB must submit the meeting application before a date will be offered (usually 30-45 days from date of application); - MTFB are working to get the application submitted this week; - Share price manipulation is a subject for the regulators to deal with. SG
19/1/2019
10:21
barriew: Nothing new but recommendation on Interactive Investor. Motif Bio (MTFB) 39.53p Motif Bio (LSE:MTFB) is developing a new antibiotic called iclaprim. Resistance to existing antibiotics means that it is imperative that new and effective antibiotics are brought onto the market. Iclaprim was originally discovered by Hoffman-La Roche and Motif addressed the reasons it failed to gain FDA approval in 2009. Two phase III trials have been completed in the US. The addressable global market for iclaprim could be worth $2.8 billion. The FDA has accepted the filing of the company's new drug application for iclaprim, relating to the treatment of acute bacterial skin and skin structure infections (ABSSSI). It has been granted priority review with a potential approval date in the first quarter of 2019. Source: TradingView (*) Past performance is not a guide to future performance Commercialisation plans have commenced. It is likely that the US hospital market will be targeted via a contract sales organisation, while in Europe a partner will be sought to help to finance approvals in the region. Motif had $19.8 million of cash at the end of June 2018 and the cash outflows have reduced. More cash is likely to be required in order to launch the product. Motif Bio's multi-billion-dollar best-seller The share price has bounced back in the past few weeks and is not far from its 12-month high – but there should be more to come. The share price is nearly double the 20p a share AIM placing price just short of four years ago. Just over two years ago there was a fundraising at 28p a share as part of the Nasdaq flotation. Barely more than one month ago the share price was below that level. If obtained, FDA approval will increase investor interest on Nasdaq, in particular, and could herald a further share price boost.
Motif Bio share price data is direct from the London Stock Exchange
Your Recent History
LSE
MTFB
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190617 10:59:14